Myelotoxicity of D-penicillamine.

D-penicillamine in rheumatoid arthritis.

D-penicillamine (D-pen) has gained wide-spread use as a potent suppressor of disease activity in rheumatoid arthritis (RA) and juvenile chronic arthritis (JCA). The drug has been established for antirheumatotd therapy on the basis o f a considerable number o f comparative clinical studies o f D-pen treatment versus placebo or other disease modifying antirheumatic drugs (DMARDs). Despite the pos...

[D-penicillamine in rheumatoid arthritis].

In view of the claim that alclofenac has a specific antirheumatoid action a detailed biochemical study has been made over a 6-month period of 2 groups of patients with rheumatoid arthritis receiving either alclofenac or D-penicillamine for the first time. We found no biochemical evidence and little clinical evidence that alclofenac had a 'penicillamine-like' effect in rheumatoid arthritis.

Eosinophilia in D-penicillamine therapy.

Cross-sectional and longitudinal studies have been carried out to determine the incidence and clinical significance of eosinophilia in patients taking penicillamine for rheumatoid arthritis. In a cross-sectional study of 204 patients eosinophilia was found with equal frequency during treatment with penicillamine, gold, and nonsteroidal anti-inflammatory drugs. A longitudinal study of 89 patient...

D penicillamine and breast enlargement.

D-Penicillamine induced myasthenia gravis.

Myasthenia gravis is a disorder of impaired neuromuscular transmission resulting in weakness and abnormal fatigability on exertion, improved by anti-acetyl cholinesterase drugs. A number of drugs are known to exacerbate myasthenia gravis or interfere with neuromuscular transmission. We report a case of D-penicillamine induced myasthenia gravis who developed ptosis, diplopia and easy fatigabilit...